SMT202500311T1 - Aceclidina per uso nel trattamento della presbiopia - Google Patents
Aceclidina per uso nel trattamento della presbiopiaInfo
- Publication number
- SMT202500311T1 SMT202500311T1 SM20250311T SMT202500311T SMT202500311T1 SM T202500311 T1 SMT202500311 T1 SM T202500311T1 SM 20250311 T SM20250311 T SM 20250311T SM T202500311 T SMT202500311 T SM T202500311T SM T202500311 T1 SMT202500311 T1 SM T202500311T1
- Authority
- SM
- San Marino
- Prior art keywords
- aceclidine
- presbyopia
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Cosmetics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361871215P | 2013-08-28 | 2013-08-28 | |
| US201361882998P | 2013-09-26 | 2013-09-26 | |
| US201361904510P | 2013-11-15 | 2013-11-15 | |
| US201361917620P | 2013-12-18 | 2013-12-18 | |
| US201461938438P | 2014-02-11 | 2014-02-11 | |
| EP19171214.0A EP3542798B1 (en) | 2013-08-28 | 2014-08-22 | Aceclidine for use in the treatment of presbyopia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SMT202500311T1 true SMT202500311T1 (it) | 2025-09-12 |
Family
ID=52584080
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SM20250311T SMT202500311T1 (it) | 2013-08-28 | 2014-08-22 | Aceclidina per uso nel trattamento della presbiopia |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US9089562B2 (https=) |
| EP (3) | EP3542798B1 (https=) |
| JP (6) | JP6426743B2 (https=) |
| KR (4) | KR20160045147A (https=) |
| CN (1) | CN105792815B (https=) |
| AU (2) | AU2014311558B2 (https=) |
| CA (1) | CA2922802C (https=) |
| DK (1) | DK3542798T3 (https=) |
| ES (1) | ES3028364T3 (https=) |
| FI (1) | FI3542798T3 (https=) |
| HK (1) | HK1225654A1 (https=) |
| HR (1) | HRP20250507T1 (https=) |
| HU (1) | HUE071646T2 (https=) |
| LT (1) | LT3542798T (https=) |
| MX (2) | MX393360B (https=) |
| PL (1) | PL3542798T3 (https=) |
| PT (1) | PT3542798T (https=) |
| RS (1) | RS66821B1 (https=) |
| SG (1) | SG11201601412XA (https=) |
| SI (1) | SI3542798T1 (https=) |
| SM (1) | SMT202500311T1 (https=) |
| WO (1) | WO2015031186A1 (https=) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA113525C2 (xx) | 2011-09-20 | 2017-02-10 | Спосіб лікування пресбіопії | |
| US9089562B2 (en) * | 2013-08-28 | 2015-07-28 | Presbyopia Therapies Llc | Compositions and methods for the treatment of presbyopia |
| CN106455567A (zh) * | 2013-12-18 | 2017-02-22 | Gnt有限责任公司 | 用于治疗青光眼的组合物和方法 |
| WO2016172712A2 (en) | 2015-04-23 | 2016-10-27 | Sydnexis, Inc. | Ophthalmic composition |
| US9421199B2 (en) | 2014-06-24 | 2016-08-23 | Sydnexis, Inc. | Ophthalmic composition |
| EP3302426A4 (en) | 2015-05-29 | 2018-12-05 | Sydnexis, Inc. | D2o stabilized pharmaceutical formulations |
| WO2016205071A1 (en) * | 2015-06-18 | 2016-12-22 | Presbyopia Therapies, LLC | Compositions and methods for the treatment of presbyopia |
| KR20180014825A (ko) * | 2015-06-18 | 2018-02-09 | 프레스바이오피아 세라피스, 엘엘씨 | 눈의 굴절 이상 치료 및 원거리 시력 개선용 조성물 및 방법 |
| CN106526888B (zh) * | 2015-09-15 | 2019-08-06 | 星欧光学股份有限公司 | 隐形眼镜产品 |
| US10845622B2 (en) | 2015-09-15 | 2020-11-24 | Largan Medical Co., Ltd. | Multifocal contact lens and contact lens product |
| US12298602B2 (en) | 2015-09-15 | 2025-05-13 | Largan Medical Co., Ltd. | Multifocal contact lens and contact lens product |
| PT3500255T (pt) * | 2016-08-19 | 2023-01-10 | Orasis Pharmaceuticals Ltd | Composições farmacêuticas oftálmicas e utilizações relacionadas com estas |
| IT201700069664A1 (it) * | 2017-06-22 | 2018-12-22 | For Health Pharma S R L | Nuova formulazione oftalmica a base di tropicamide |
| JP7170436B2 (ja) * | 2017-06-28 | 2022-11-14 | 千寿製薬株式会社 | 水溶性高分子を含む点眼剤 |
| CA3070556A1 (en) * | 2017-07-20 | 2019-01-24 | Alan Laboratories, Inc. | Compositions and methods for treatment of myopia |
| JP6603785B2 (ja) * | 2017-12-08 | 2019-11-06 | 千寿製薬株式会社 | 水溶性高分子を含む水性液剤 |
| PL3681500T3 (pl) | 2018-04-24 | 2022-08-01 | Allergan, Inc. | Zastosowanie chlorowodorku pilokarpiny w leczeniu starczowzroczności |
| TW202021584A (zh) * | 2018-08-21 | 2020-06-16 | 美商歐樂根公司 | α2 腎上腺素受體促效劑用於改善視力之用途 |
| JP2020033290A (ja) * | 2018-08-29 | 2020-03-05 | 興和株式会社 | 水性組成物 |
| US20210251970A1 (en) | 2018-10-10 | 2021-08-19 | Presbyopia Therapies Inc | Compositions and methods for storage stable ophthalmic drugs |
| US10836760B2 (en) | 2018-10-10 | 2020-11-17 | Presbyopia Therapies Llc | Compositions and methods for the treatment of presbyopia |
| WO2020252057A1 (en) * | 2019-06-10 | 2020-12-17 | Visus Therapeutics, Inc. | Using parasympathomimetic drugs alone or, in combination with one or more alpha agonists in pseudophakic patients, to create multi-focality |
| CN114502155A (zh) * | 2019-06-10 | 2022-05-13 | 视觉治疗股份有限公司 | 增强抗老视作用的卡巴胆碱-溴莫尼定制剂 |
| CA3147107A1 (en) * | 2019-07-26 | 2021-02-04 | Allergan, Inc. | Compositions and methods for treatment of presbyopia |
| WO2021236671A1 (en) * | 2020-05-18 | 2021-11-25 | Vyluma Inc. | Low-dose carbachol compositions and methods for treatment of night vision disturbance |
| US20230190738A1 (en) * | 2021-12-16 | 2023-06-22 | Lenz Therapeutics, Inc. | Compositions and methods for the treatment of eye conditions |
| PL4312986T3 (pl) * | 2021-04-01 | 2025-02-17 | Active Biotech Ab | Preparat lakwinimodu do stosowania do oczu |
| WO2022232205A1 (en) * | 2021-04-28 | 2022-11-03 | Lenz Therapeutics, Inc. | A method of reducing brow ache |
| KR102415950B1 (ko) | 2021-07-13 | 2022-07-05 | 백두하 | 백국화 추출물, 모과 추출물 및 용안육 추출물의 혼합물을 유효성분으로 포함하는 눈 건강 기능 식품 및 이의 제조방법 |
| TW202333662A (zh) * | 2021-11-10 | 2023-09-01 | 美商偉視醫療股份有限公司 | 增強抗老花眼效果之卡巴可(carbachol)調配物 |
| WO2023091439A1 (en) * | 2021-11-17 | 2023-05-25 | Lenz Therapeutics, Inc. | Aceclidine derivatives, compositions thereof and methods of use thereof |
| US11648247B1 (en) | 2021-12-16 | 2023-05-16 | Lenz Therapeutics, Inc. | Compositions and methods for the treatment of presbyopia |
| CN114588156B (zh) * | 2022-04-22 | 2024-06-11 | 温州医科大学附属眼视光医院 | 一种眼用制剂及其在治疗老花眼中的应用 |
| KR102678138B1 (ko) * | 2022-09-29 | 2024-06-25 | 주식회사태준제약 | 브리모니딘을 포함하는 안과용 조성물 |
| KR20240099055A (ko) * | 2022-12-21 | 2024-06-28 | 주식회사 대웅테라퓨틱스 | 이나보글리플로진을 포함하는 점안제 형태의 약학 조성물 |
| WO2024220441A1 (en) * | 2023-04-17 | 2024-10-24 | Lenz Therapeutics Operations, Inc. | Methods for the treatment of presbyopia |
| CN119789854A (zh) * | 2023-08-04 | 2025-04-08 | Ads医疗有限责任公司 | 用于递送眼科活性物的组合物和方法 |
| CN119700989A (zh) * | 2023-09-28 | 2025-03-28 | 苏州普乐康医药科技有限公司 | 一种α-肾上腺素受体激动剂眼用组合物及其用途 |
| US12414942B1 (en) | 2024-03-15 | 2025-09-16 | Lenz Therapeutics Operations, Inc. | Compositions, methods, and systems for treating presbyopia |
| WO2025259674A1 (en) * | 2024-06-11 | 2025-12-18 | Ads Therapeutics Llc | Compositions and methods for delivery of pharmaceutical actives |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1229075B (it) * | 1985-04-05 | 1991-07-17 | Fidia Farmaceutici | Medicamenti per uso topico, ottenuti tramite l'impiego dell'acido ialuronico |
| CA2031469A1 (en) * | 1989-12-28 | 1991-06-29 | Larry A. Wheeler | Use of inclusion complexes of prostaglandins with cyclodextrins in the treatment of ocular hypertension |
| US5073560A (en) * | 1990-07-20 | 1991-12-17 | Fisons Corporation | Spiro-isoxazolidine derivatives as cholinergic agents |
| US6291466B1 (en) * | 1998-07-30 | 2001-09-18 | Allergan Sales, Inc. | Cholinergic agents in the treatment of presbyopia |
| ITMI20010708A1 (it) * | 2001-04-03 | 2002-10-03 | Alessandro Randazzo | Trattamento farmacologico degli aloni notturni e delle immagini fantasma con parasimpaticomimetici diluiti aceclidina/pilocarpina dopo inter |
| AR034371A1 (es) | 2001-06-08 | 2004-02-18 | Novartis Ag | Composiciones farmaceuticas |
| JP2003201241A (ja) | 2001-10-22 | 2003-07-18 | Rohto Pharmaceut Co Ltd | 眼科用組成物 |
| JP2004168709A (ja) * | 2002-11-20 | 2004-06-17 | Nidek Co Ltd | 抗アレルギー点眼点鼻用組成物 |
| US20060177430A1 (en) | 2002-12-20 | 2006-08-10 | Chakshu Research Inc | Treatment of ocular disorders with ophthalmic formulations containing methylsulfonylmethane as a transport enhancer |
| US20060172972A1 (en) * | 2002-12-20 | 2006-08-03 | Chakshu Research Inc | Formulation and method for administration of ophthalmologically active agents |
| US20040185068A1 (en) * | 2003-03-18 | 2004-09-23 | Zhi-Jian Yu | Self-emulsifying compositions, methods of use and preparation |
| US8663639B2 (en) * | 2005-02-09 | 2014-03-04 | Santen Pharmaceutical Co., Ltd. | Formulations for treating ocular diseases and conditions |
| JP2008536866A (ja) | 2005-04-15 | 2008-09-11 | ボード、オブ、トラスティーズ、オブ、ミシガン、ステイト、ユニバーシティ | アミン作動性医薬組成物および方法 |
| ES2329161T3 (es) | 2006-12-18 | 2009-11-23 | Jorge Luis Benozzi | Composiciones oftalmicas de estimulantes parasimpaticos y antiinflamatorios para su uso en el tratamiento de la presbicia. |
| EP2097044A4 (en) * | 2006-12-26 | 2012-10-10 | Quadra Logic Tech Inc | DRUG RELIEF IMPLANTS FOR INHIBITING OPTICAL DEFECTS |
| GB0724558D0 (en) | 2007-12-15 | 2008-01-30 | Sharma Anant | Optical correction |
| US20110212142A1 (en) * | 2008-11-17 | 2011-09-01 | Laila Pharmaceuticals Pvt.Ltd. | Curcuminoids and its metabolites for the application in ocular diseases |
| US8501800B2 (en) | 2009-03-05 | 2013-08-06 | Insite Vision Incorporated | Controlled-release ophthalmic vehicles |
| WO2010125416A1 (en) * | 2009-04-27 | 2010-11-04 | Raouf Rekik | Drug delivery to the anterior and posterior segments of the eye |
| WO2010135731A1 (en) | 2009-05-22 | 2010-11-25 | Kaufman Herbert E | Preparations and methods for ameliorating or reducing presbyopia |
| US8299079B2 (en) | 2009-05-22 | 2012-10-30 | Kaufman Herbert E | Preparations and methods for ameliorating or reducing presbyopia |
| AU2009347921B8 (en) | 2009-06-10 | 2014-07-24 | Mitotech Sa | Pharmaceutical composition for use in medical and veterinary ophthalmology |
| WO2011011519A1 (en) * | 2009-07-21 | 2011-01-27 | Chimerix, Inc. | Compounds, compositions and methods for treating ocular conditions |
| JP2013523825A (ja) * | 2010-04-07 | 2013-06-17 | アラーガン インコーポレイテッド | 眼科製剤のための保存剤組成物の組み合わせ |
| WO2011127151A2 (en) * | 2010-04-07 | 2011-10-13 | Allergan, Inc. | Combinations of preservatives for ophthalmic compositions |
| JP2014506936A (ja) | 2011-03-03 | 2014-03-20 | アラーガン インコーポレイテッド | シリコーンベースの眼科製剤 |
| UA113525C2 (xx) | 2011-09-20 | 2017-02-10 | Спосіб лікування пресбіопії | |
| US9089562B2 (en) * | 2013-08-28 | 2015-07-28 | Presbyopia Therapies Llc | Compositions and methods for the treatment of presbyopia |
-
2014
- 2014-03-24 US US14/223,639 patent/US9089562B2/en active Active
- 2014-08-22 LT LTEP19171214.0T patent/LT3542798T/lt unknown
- 2014-08-22 PT PT191712140T patent/PT3542798T/pt unknown
- 2014-08-22 SI SI201432111T patent/SI3542798T1/sl unknown
- 2014-08-22 JP JP2016538985A patent/JP6426743B2/ja active Active
- 2014-08-22 HR HRP20250507TT patent/HRP20250507T1/hr unknown
- 2014-08-22 DK DK19171214.0T patent/DK3542798T3/da active
- 2014-08-22 HU HUE19171214A patent/HUE071646T2/hu unknown
- 2014-08-22 KR KR1020167008062A patent/KR20160045147A/ko not_active Ceased
- 2014-08-22 KR KR1020237038216A patent/KR102905081B1/ko active Active
- 2014-08-22 PL PL19171214.0T patent/PL3542798T3/pl unknown
- 2014-08-22 CN CN201480059131.5A patent/CN105792815B/zh active Active
- 2014-08-22 SG SG11201601412XA patent/SG11201601412XA/en unknown
- 2014-08-22 SM SM20250311T patent/SMT202500311T1/it unknown
- 2014-08-22 MX MX2020002922A patent/MX393360B/es unknown
- 2014-08-22 ES ES19171214T patent/ES3028364T3/es active Active
- 2014-08-22 EP EP19171214.0A patent/EP3542798B1/en active Active
- 2014-08-22 EP EP25156770.7A patent/EP4563162A3/en active Pending
- 2014-08-22 AU AU2014311558A patent/AU2014311558B2/en not_active Ceased
- 2014-08-22 KR KR1020227030984A patent/KR102600484B1/ko active Active
- 2014-08-22 KR KR1020257042845A patent/KR20260008183A/ko active Pending
- 2014-08-22 RS RS20250501A patent/RS66821B1/sr unknown
- 2014-08-22 CA CA2922802A patent/CA2922802C/en active Active
- 2014-08-22 EP EP14840282.9A patent/EP3038610A4/en not_active Withdrawn
- 2014-08-22 WO PCT/US2014/052256 patent/WO2015031186A1/en not_active Ceased
- 2014-08-22 MX MX2016002623A patent/MX2016002623A/es active IP Right Grant
- 2014-08-22 HK HK16114180.3A patent/HK1225654A1/zh unknown
- 2014-08-22 FI FIEP19171214.0T patent/FI3542798T3/fi active
-
2018
- 2018-10-24 JP JP2018199733A patent/JP2019031538A/ja not_active Ceased
-
2019
- 2019-01-31 AU AU2019200623A patent/AU2019200623B2/en active Active
- 2019-12-06 JP JP2019220904A patent/JP7358221B2/ja active Active
-
2021
- 2021-08-19 JP JP2021133867A patent/JP7329019B2/ja active Active
-
2023
- 2023-05-17 JP JP2023081444A patent/JP2023103400A/ja active Pending
-
2025
- 2025-06-04 JP JP2025093153A patent/JP2025131705A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SMT202500311T1 (it) | Aceclidina per uso nel trattamento della presbiopia | |
| GB2516814B (en) | Use of phytocannabinoids for increasing radiosensitivity in the treatment of cancer | |
| HUE039560T2 (hu) | Mikro méretû zárófedés és kapcsolódó eljárások bõr kezelésére | |
| SG10201709090UA (en) | Sobetirome in the treatment of myelination diseases | |
| LT2983866T (lt) | Abrazyvinis įrankis | |
| GB201304872D0 (en) | Treatment | |
| GB201317960D0 (en) | Water treatment | |
| GB201302839D0 (en) | Water Treatment | |
| GB201304038D0 (en) | Treated cells and therapeutic uses | |
| PT2836176T (pt) | Técnica para tratar presbiopia | |
| GB201307310D0 (en) | Treatment | |
| PT2857023T (pt) | Utilização de odiparcil no tratamento de uma mucopolissacaridose | |
| ZA201604412B (en) | Water treatment | |
| GB2514124B (en) | Turf Treatment | |
| GB201416965D0 (en) | Water treatment | |
| GB201308539D0 (en) | Liquid treatment | |
| GB201314623D0 (en) | Novel mucinase for use in therapy or prophylaxis | |
| GB201321115D0 (en) | Treatment | |
| AU353177S (en) | Grinding body | |
| AU352656S (en) | Grinding body | |
| GB201313159D0 (en) | Finishing Treatment | |
| GB201309238D0 (en) | Treatment | |
| ZA201406350B (en) | Water treatment | |
| GB201322958D0 (en) | Uses of oligouronates in cancer treatment | |
| GB201315704D0 (en) | Water treatment |